Zurich-based Rivia has secured €13 million ($15 million) in Series A funding to enhance its AI-driven analytics and clinical trial data infrastructure for biotech companies. The round was led by Earlybird, with participation from Defiant and existing investors Speedinvest, Amino Collective, and Nina Capital. This capital will fuel team growth, product development, and international expansion, particularly in the US.